Michael Klein

Michael Klein is a Principal at 5AM Ventures based in the San Francisco Bay Area, where he focuses on early-stage biotechnology and healthcare investments. Before assuming his current position in early 2023, he served as an Associate at Kleiner Perkins and worked as an investment professional at OrbiMed Advisors. Klein holds an MD from Harvard Medical School and completed clinical training in internal medicine before transitioning to the venture capital industry. He has contributed to a firm portfolio of over 50 companies, including notable investments in unicorns like Aledade, and recently led a Series A funding round for a novel oncology platform in the third quarter of 2024. Klein leverages his clinical medical background to evaluate early-stage therapeutics, diagnostics, and healthcare platforms, maintaining a primary focus on translating scientific research into commercially viable enterprises.